Gennaro Pagano, MD, MSc, PhD, Expert Medical Director, Group Leader, Chair of Medical Directors Fellows at Roche Pharma Research and Early Development (pRED) and Researcher at King’s College London, discusses whether age at onset of Parkinson’s disease influences early disease progression. Data from the Parkinson’s Progression Markers Initiative Database were analyzed. Results showed that older age at onset was associated with faster progression of the disease, suggesting that age at onset should be included as a stratification factor in future clinical trials. This interview took place during the AD/PD™ 2021 conference.
G.Pagano is a full-time employee and shareholder of F. Hoffmann-La Roche Ltd